pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2013-0-4-109-114pulmo-262Research ArticleОБЗОРЫREVIEWИнгаляционный тобрамицин в лечении хронической синегнойной инфекции при муковисцидозеTobramycin inhalations in therapy of chronic infection Pseudomonas aeruginosa in cystic fibrosisАмелинаЕ. Л.AmelinaE. L.

к. м. н., зав. лабораторией муковисцидоза 

105077, Москва, ул. 11-я Парковая, 32, корп. 4. Тел.: (495) 465-53-84.

eamelina@mail.ruКрасовскийС. А.KrasovskyS. A.

к. м. н., научный сотрудник лаборатории муковисцидоза 

105077, Москва, ул. 11-я Парковая, 32, корп. 4. Тел.: (495) 465-74-15.

sa-krasovsky@mail.ruФГБУ "НИИ пульмонологии" ФМБА РоссииRussian Federation20132808201304109114Copyright © Амелина Е.Л., Красовский С.А., 20132013Амелина Е.Л., Красовский С.А.Amelina E.L., Krasovsky S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/262

Ингаляционный тобрамицин в лечении хронической синегнойной инфекции при муковисцидозе.

Tobramycin inhalations in therapy of chronic infection Pseudomonas aeruginosa in cystic fibrosis.

муковисцидозаэрозольингаляционный антибиотиктобрамицинcystic fibrosisaerosolinhaled antibiotictobramycinReferencesBoucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 2004; 23: 146–158.Boucher R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 2004; 23: 146–158.Høiby N., Krogh Johansen H., Moser C. et al. Pseudomonas aeruginosaand the in vitro and in vivo biofilm mode of growth. Microbes Infect. 2001; 3: 23–35.Høiby N., Krogh Johansen H., Moser C. et al. Pseudomonas aeruginosaand the in vitro and in vivo biofilm mode of growth. Microbes Infect. 2001; 3: 23–35.Armstrong D.S., Grimwood K., Carzino R. et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. Br. Med. J. 1995; 310: 1571–1572.Armstrong D.S., Grimwood K., Carzino R. et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. Br. Med. J. 1995; 310: 1571–1572.Armstrong D.S., Hook S.M., Jamsen K.M. et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr. Pulmon. 2005; 40: 500–510.Armstrong D.S., Hook S.M., Jamsen K.M. et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr. Pulmon. 2005; 40: 500–510.Hansen C.R., Pressler T., Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J. Cyst. Fibros. 2008; 7: 523–530.Hansen C.R., Pressler T., Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J. Cyst. Fibros. 2008; 7: 523–530.Cooney G.F., Lum B.L., Tomaselli M., Fiel S.B. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. 1994; 34: 255–259.Cooney G.F., Lum B.L., Tomaselli M., Fiel S.B. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. 1994; 34: 255–259.Geller D.E., Pitlick W.H., Nardella P.A. et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219–226.Geller D.E., Pitlick W.H., Nardella P.A. et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002; 122: 219–226.Jelsbak L., Johansen H.K., Frost A.L. et al. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect. and Immun. 2007; 75: 2214–2224.Jelsbak L., Johansen H.K., Frost A.L. et al. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect. and Immun. 2007; 75: 2214–2224.Ramsey B.W., Dorkin H.L., Eisenberg J.D. et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1993; 328: 1740–1746.Ramsey B.W., Dorkin H.L., Eisenberg J.D. et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1993; 328: 1740–1746.Lenoir G., Antypkin Y.G., Miano A. et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Drugs 2007; 9: 11–20.Lenoir G., Antypkin Y.G., Miano A. et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Drugs 2007; 9: 11–20.Hodson M.E., Gallagher C.G., Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20: 658–664.Hodson M.E., Gallagher C.G., Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J. 2002; 20: 658–664.Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999; 340: 23–30.Ramsey B.W., Pepe M.S., Quan J.M. et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N. Engl. J. Med. 1999; 340: 23–30.Chuchalin A., Gyurkovics K., Bartnicka M.T. et al. A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatr. Drugs 2007; 9: 21–31.Chuchalin A., Gyurkovics K., Bartnicka M.T. et al. A formulation of aerosolized tobramycin (Bramitob®) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Pediatr. Drugs 2007; 9: 21–31.Geller D.E., Konstan M.W., Smith J. et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmon. 2007; 42: 307–313.Geller D.E., Konstan M.W., Smith J. et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmon. 2007; 42: 307–313.Konstan M.W., Flume P.A., Keppler M. et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibros. 2011; 10 (1): 54–61.Konstan M.W., Flume P.A., Keppler M. et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J. Cyst. Fibros. 2011; 10 (1): 54–61.Konstan M., Geller D.E., Minic P. et al. Tobramycin inhalation powder for Pseudomonas aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr. Pulmon. 2011; 46: 230–238.Konstan M., Geller D.E., Minic P. et al. Tobramycin inhalation powder for Pseudomonas aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr. Pulmon. 2011; 46: 230–238.Moss R.B. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001; 120: 107S–113S.Moss R.B. Administration of aerosolized antibiotics in cystic fibrosis patients. Chest 2001; 120: 107S–113S.Moss R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55–63.Moss R.B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121: 55–63.AHFS drug information 2006. Tobramycin sulfate. http://www.ashp.org/ahfs/first-rel/Revised3tobramycinoct2006.pdf [accessed 1 Nov 2007].AHFS drug information 2006. Tobramycin sulfate. http://www.ashp.org/ahfs/first-rel/Revised3tobramycinoct2006.pdf [accessed 1 Nov 2007].Kerem E., Reisman J., Corey M. et al. Prediction of mortality in patients with cystic fibrosis. N. Engl. J. Med. 1992; 326: 1187–1191.Kerem E., Reisman J., Corey M. et al. Prediction of mortality in patients with cystic fibrosis. N. Engl. J. Med. 1992; 326: 1187–1191.Ramsey B.W., Boat T.F. Outcome measures for clinical trials in cystic fibrosis: summary of a Cystic Fibrosis Foundation consensus conference. J. Pediatr. 1994; 124: 177–192.Ramsey B.W., Boat T.F. Outcome measures for clinical trials in cystic fibrosis: summary of a Cystic Fibrosis Foundation consensus conference. J. Pediatr. 1994; 124: 177–192.Iles R., Legh3Smith J., Drummond M. et al. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. J. Cyst. Fibros. 2003; 2: 120–128.Iles R., Legh3Smith J., Drummond M. et al. Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis. J. Cyst. Fibros. 2003; 2: 120–128.Anderson G.G., Moreau3Marquis S., Stanton B.A., O'Toole G.A. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect. and Immun. 2008; 76: 1423–1433.Anderson G.G., Moreau3Marquis S., Stanton B.A., O'Toole G.A. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect. and Immun. 2008; 76: 1423–1433.Murphy T.D., Anbar R.D., Lester L.A. et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr. Pulmonol. 2004; 38: 314–320.Murphy T.D., Anbar R.D., Lester L.A. et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr. Pulmonol. 2004; 38: 314–320.Mazurek H., Chiron R., Varoli G. et al. Efficacy on lung function and safety of multiple courses of tobramycin 300 mg / 4 ml nebuliser solution (Bramitob®) in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection: Results from a 48-week extension phase. In: Poster presented on 35th ECFS Conference, Dublin, Ireland, June 2012.Mazurek H., Chiron R., Varoli G. et al. Efficacy on lung function and safety of multiple courses of tobramycin 300 mg / 4 ml nebuliser solution (Bramitob®) in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection: Results from a 48-week extension phase. In: Poster presented on 35th ECFS Conference, Dublin, Ireland, June 2012.Govoni M., Poli G., Cicirello H. et al. Pharmacokinetics of tobramycin nebulizer solution 300 mg / 4 ml (Bramitob®) administered by Pari eFlow® Rapid vs Pari LC® Plus nebulizer in cystic fibrosis patients. Pulmon. Pharmacol. Ther. 2013; 26 (2): 249–255.Govoni M., Poli G., Cicirello H. et al. Pharmacokinetics of tobramycin nebulizer solution 300 mg / 4 ml (Bramitob®) administered by Pari eFlow® Rapid vs Pari LC® Plus nebulizer in cystic fibrosis patients. Pulmon. Pharmacol. Ther. 2013; 26 (2): 249–255.Engel T., Heinig J.H., Madsen F., Nikander K. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler®). Eur. Respir. J. 1990; 3: 1037–1041. Online Resources.Engel T., Heinig J.H., Madsen F., Nikander K. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler®). Eur. Respir. J. 1990; 3: 1037–1041. Online Resources.Tiddens H.A., Geller D.E., Challoner P. et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J. Aerosol. Med. 2006; 19 (4): 456–465.Tiddens H.A., Geller D.E., Challoner P. et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J. Aerosol. Med. 2006; 19 (4): 456–465.

The authors declare that there are no conflicts of interest present.